Next Article in Journal
Is the Immunization of Pregnant Women against COVID-19 Justified?
Previous Article in Journal
Towards a Prophylactic Vaccine for the Prevention of HCMV Infection
Article

A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates

1
Janssen Infectious Diseases, Janssen Research and Development, Division of Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340 Beerse, Belgium
2
Ichor Medical Systems Inc., 6310 Nancy Ridge Drive, Suite 107, San Diego, CA 92121, USA
3
Discovery Sciences, Janssen Research and Development, Division of Janssen Pharmaceutica NV, Turn-houtseweg 30, 2340 Beerse, Belgium
4
Janssen Infectious Diseases, Division of Janssen Pharmaceutica NV, 260 E. Grand Avenue, South San Francisco, CA 94080, USA
*
Author to whom correspondence should be addressed.
Former employee of Janssen Pharmaceutica NV.
These authors contributed equally to manuscript.
Academic Editor: Yee-Joo Tan
Vaccines 2021, 9(9), 969; https://doi.org/10.3390/vaccines9090969
Received: 26 May 2021 / Revised: 20 August 2021 / Accepted: 25 August 2021 / Published: 29 August 2021
(This article belongs to the Section Hepatitis Virus Vaccines)
Despite the availability of an effective prophylactic vaccine for more than 30 years, nearly 300 million people worldwide are chronically infected with the hepatitis B virus (HBV), leading to 1 death every 30 s mainly from viral hepatitis-related cirrhosis and liver cancer. Chronic HBV patients exhibit weak, transient, or dysfunctional CD8+ T-cell responses to HBV, which contrasts with high CD8+ T-cell responses seen for resolvers of acute HBV infection. Therefore, a therapeutic DNA vaccine was designed, expressing both HBV core and polymerase proteins, and was sequence optimized to ensure high protein expression and secretion. Although the vaccine, administered intramuscularly via electroporation, had no effect on plasma viral parameters in a mouse model of persistent HBV infection, it did induce robust HBV-specific immune responses in healthy and adeno-associated hepatitis B virus (AAV-HBV) infected mice as well as in healthy non-human primates. View Full-Text
Keywords: therapeutic vaccination; hepatitis B surface antigen (HBsAg); hepatitis B virus (HBV) specific T-cells; HBV functional cure; non-human primate; electroporation therapeutic vaccination; hepatitis B surface antigen (HBsAg); hepatitis B virus (HBV) specific T-cells; HBV functional cure; non-human primate; electroporation
Show Figures

Figure 1

MDPI and ACS Style

De Pooter, D.; Van Gulck, E.; Chen, A.; Evans, C.F.; Neefs, J.-M.; Horton, H.; Boden, D. A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates. Vaccines 2021, 9, 969. https://doi.org/10.3390/vaccines9090969

AMA Style

De Pooter D, Van Gulck E, Chen A, Evans CF, Neefs J-M, Horton H, Boden D. A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates. Vaccines. 2021; 9(9):969. https://doi.org/10.3390/vaccines9090969

Chicago/Turabian Style

De Pooter, Dorien, Ellen Van Gulck, Antony Chen, Claire F. Evans, Jean-Marc Neefs, Helen Horton, and Daniel Boden. 2021. "A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates" Vaccines 9, no. 9: 969. https://doi.org/10.3390/vaccines9090969

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop